Velcade is named as an intervention in 17 current clinical trials in our Italy, Germany, France, Canada, Spain, Australia, Israel, USA, Japan, Denmark, Poland, Turkey, UK, Netherlands, China, Belgium, Czechia, Norway, Sweden, Brazil, Mexico, South Korea, Taiwan, India, Austria, Portugal and Switzerland registers. 6 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Stichting European Myeloma Network (2). The most-studied condition is Multiple Myeloma. The EU clinical trials register (CTIS) separately lists 3 authorised or ongoing trials.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Velcade. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Lead sponsor | Trials |
|---|---|
| Stichting European Myeloma Network | 2 |
| Celgene | 1 |
| Janssen Research & Development, LLC | 1 |
| AstraZeneca | 1 |
| Sanofi | 1 |
| University of Heidelberg Medical Center | 1 |
| University Hopsital Schleswig Holstein Campus Lübeck | 1 |
| Intergroupe Francophone du Myelome | 1 |
| University of Turin, Italy | 1 |
| Ida Bruun Kristensen | 1 |
| Canadian Myeloma Research Group | 1 |
| AHS Cancer Control Alberta | 1 |
| St. Jude Children's Research Hospital | 1 |
| Karyopharm Therapeutics Inc | 1 |
| Paul Richardson, MD | 1 |
+ 1 more sponsors in the trial list above.
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
17 current trials in our Italy, Germany, France, Canada, Spain, Australia, Israel, USA, Japan, Denmark, Poland, Turkey, UK, Netherlands, China, Belgium, Czechia, Norway, Sweden, Brazil, Mexico, South Korea, Taiwan, India, Austria, Portugal and Switzerland registers name Velcade as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 6 of the 17 trials are recruiting: 1 with sites in Italy, 2 with sites in Germany, 2 with sites in France, 3 with sites in Canada, 1 with sites in Spain, 1 with sites in Australia, 1 with sites in Israel, 1 with sites in USA, 1 with sites in Japan, 1 with sites in Poland, 1 with sites in UK, 1 with sites in China, 1 with sites in Norway, 1 with sites in Brazil, 1 with sites in South Korea and 1 with sites in Taiwan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Stichting European Myeloma Network (2), Celgene (1), Janssen Research & Development, LLC (1) and AstraZeneca (1), among 16 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Velcade works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Velcade works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Velcade (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.